Fig. 3: Percentage change in VTT length over the axitinib treatment period. | British Journal of Cancer

Fig. 3: Percentage change in VTT length over the axitinib treatment period.

From: A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

Fig. 3

a Line chart showing percentage change in VTT length for IVC responders, RV responders and non-responders. Waterfall plot of VTT response against tumour response at (b) 3 and (c) 9 weeks of treatment. N0601 (surgery expedited), N0605 (surgery expedited) and N0903 (exited trial due to new brain metastasis) did not have scans at week 9. Bar colour indicates the patient’s overall RECIST status distinct from VTT assessment.

Back to article page